[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY2012014I2 - Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρης - Google Patents

Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρης

Info

Publication number
CY2012014I2
CY2012014I2 CY2012014C CY2012014C CY2012014I2 CY 2012014 I2 CY2012014 I2 CY 2012014I2 CY 2012014 C CY2012014 C CY 2012014C CY 2012014 C CY2012014 C CY 2012014C CY 2012014 I2 CY2012014 I2 CY 2012014I2
Authority
CY
Cyprus
Prior art keywords
tegafur
administration
toxicity due
gastrointestinal toxicity
reducing gastrointestinal
Prior art date
Application number
CY2012014C
Other languages
English (en)
Other versions
CY2012014I1 (el
Original Assignee
Taiho Pharmaceutical Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Company, Limited filed Critical Taiho Pharmaceutical Company, Limited
Publication of CY2012014I1 publication Critical patent/CY2012014I1/el
Publication of CY2012014I2 publication Critical patent/CY2012014I2/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY2012014C 2004-04-29 2012-05-31 Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρης CY2012014I2 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56618004P 2004-04-29 2004-04-29
PCT/JP2005/008450 WO2005105086A1 (en) 2004-04-29 2005-04-27 Method for reducing gastrointestinal toxicity due to the administration of tegafur

Publications (2)

Publication Number Publication Date
CY2012014I1 CY2012014I1 (el) 2016-04-13
CY2012014I2 true CY2012014I2 (el) 2016-04-13

Family

ID=35241420

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20121100222T CY1112451T1 (el) 2004-04-29 2012-03-07 Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρης
CY2012014C CY2012014I2 (el) 2004-04-29 2012-05-31 Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20121100222T CY1112451T1 (el) 2004-04-29 2012-03-07 Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρης

Country Status (16)

Country Link
US (1) US20080166427A1 (el)
EP (1) EP1750703B1 (el)
JP (1) JP5376758B2 (el)
AT (1) ATE540679T1 (el)
AU (1) AU2005237364B2 (el)
CY (2) CY1112451T1 (el)
DK (1) DK1750703T3 (el)
ES (1) ES2378072T3 (el)
HR (1) HRP20120293T1 (el)
ME (1) ME01335B (el)
PL (1) PL1750703T3 (el)
PT (1) PT1750703E (el)
RS (1) RS52217B (el)
RU (1) RU2348409C2 (el)
SI (1) SI1750703T1 (el)
WO (1) WO2005105086A1 (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010131769A1 (en) * 2009-05-13 2010-11-18 Taiho Pharmaceutical Co., Ltd. Treatment of diffuse-type gastric cancers using s-1 and cisplatin
WO2011009140A1 (en) * 2009-07-17 2011-01-20 Myriad Genetics, Inc. Method of assaying 5-fu
WO2011022174A1 (en) * 2009-08-21 2011-02-24 Myriad Genetics, Inc. Method of processing blood samples containing 5-fu
EP2422848A1 (en) 2010-08-18 2012-02-29 Grindeks, a joint stock company Composition of tegafur, Indole-3-carbinol and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours
EP2422784A1 (en) 2010-08-18 2012-02-29 Grindeks, a joint stock company Composition of TEGAFUR, caffeic acid phenethyl ester (CAPE) and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours
EP2422815A1 (en) 2010-08-18 2012-02-29 Grindeks, a joint stock company Pharmaceutical composition of tegafur and natural flavonoid derivative catechin for potentiating antitumour effect and for treating tumours
EP3113776B1 (en) * 2014-03-06 2021-01-13 University of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
US10172839B2 (en) 2014-03-06 2019-01-08 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
JP2017509671A (ja) * 2014-03-28 2017-04-06 ウニベルシタ デリィ ストゥディ ディ ジェノバ カロリー摂取量減少と協同したがん治療方法で使用されるチロシンキナーゼ阻害剤
CN107613983B (zh) * 2015-04-30 2021-05-04 大鹏药品工业株式会社 抗肿瘤剂的副作用减轻剂
JP6439761B2 (ja) * 2016-08-09 2018-12-19 トヨタ自動車株式会社 ＮＯｘ吸蔵還元触媒の製造方法
AU2021275620A1 (en) * 2020-05-19 2022-12-08 Cellix Bio Private Limited Pharmaceutical formulations and their preparations for treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635946A (en) * 1969-07-22 1972-01-18 Solomon Aronovich Giller N1-(2'-furanidyl)-derivatives of 5-substituted uracils
DE3585869D1 (de) * 1984-10-30 1992-05-21 Otsuka Pharma Co Ltd Zusammensetzung zur steigerung der antikrebsaktivitaet einer antikrebsverbindung.
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
DE69003670T2 (de) * 1989-01-05 1994-01-27 Otsuka Pharma Co Ltd Nicht einspritzbares karzinostatisches mittel zur vorbeugung der entzündung durch 5-fluoruracil und verfahren zur behandlung von krebs.
DE69227571T2 (de) * 1991-05-27 1999-04-29 Taiho Pharmaceutical Co., Ltd., Tokio/Tokyo Zusammensetzung, verfahren und instrument zur potenzierung der antitumoraktivität und zur behandlung von tumoren

Also Published As

Publication number Publication date
WO2005105086A1 (en) 2005-11-10
US20080166427A1 (en) 2008-07-10
RU2006142101A (ru) 2008-06-20
EP1750703B1 (en) 2012-01-11
CY2012014I1 (el) 2016-04-13
DK1750703T3 (da) 2012-05-07
ME01335B (me) 2013-12-20
HRP20120293T1 (hr) 2012-04-30
AU2005237364B2 (en) 2010-07-08
EP1750703A4 (en) 2008-02-27
PL1750703T3 (pl) 2012-05-31
PT1750703E (pt) 2012-02-23
JP2007534634A (ja) 2007-11-29
SI1750703T1 (sl) 2012-02-29
AU2005237364A1 (en) 2005-11-10
ATE540679T1 (de) 2012-01-15
RU2348409C2 (ru) 2009-03-10
EP1750703A1 (en) 2007-02-14
JP5376758B2 (ja) 2013-12-25
ES2378072T3 (es) 2012-04-04
RS52217B (en) 2012-10-31
CY1112451T1 (el) 2015-12-09

Similar Documents

Publication Publication Date Title
CY2012014I2 (el) Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρης
CY2022001I2 (el) Παραγωγα του uk-2a
IS8578A (is) 3- karbamoýl - 2- pýridón afleiður
DK2253614T3 (da) IAP-inhibitorer
DK1919907T5 (da) Heterocyklisk forbindelse
DE602005025715D1 (de) Kondensator
BRPI0511900A (pt) composições farmacêuticas
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
DE502005007060D1 (de) Synchronisationsmodul
DK1725553T3 (da) Tetrahydropyridoindolderivater
HK1107348A1 (en) Indozolone derivatives as 11b-hsd1 inhibitors
ATE553079T1 (de) Heteroarylphenylharnstoffderivat
DK2783682T3 (da) Farmaceutisk sammensætning omfattende pimobendan
ATE512960T1 (de) Pyrimidinderivate
ATE417830T1 (de) Sulfonylbenzimidazolderivate
ATE412651T1 (de) Pyrrolopyridinderivate
NO20070299L (no) Novel heterocyclic compounds
EP1776112A4 (en) HETEROCYCLIC COMPOUNDS AS PHARMACEUTICAL AGENTS
ATE430142T1 (de) Phenylpiperazin-methanon-derivate
DE602005001253D1 (de) Leichtausteckbarer Verbinder
ATE404542T1 (de) 4-phenylpyrimidin-2-carbonitrilderivate
DK1740574T3 (da) 4-amino-5-cyanopyrimidinderivater
DE502005005356D1 (de) Tripode-rolle
ITMI20041447A1 (it) Composizione farmaceutica comprendente gabapentina
SE0601411L (sv) Förfarande vid beredning